Denali Therapeutics (DNLI) Receivables (2018 - 2025)
Historic Receivables for Denali Therapeutics (DNLI) over the last 8 years, with Q3 2025 value amounting to $1.9 million.
- Denali Therapeutics' Receivables rose 3571.43% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 3571.43%. This contributed to the annual value of $1.5 million for FY2024, which is 5614.04% down from last year.
- As of Q3 2025, Denali Therapeutics' Receivables stood at $1.9 million, which was up 3571.43% from $1.4 million recorded in Q2 2025.
- Denali Therapeutics' 5-year Receivables high stood at $16.8 million for Q2 2021, and its period low was $357000.0 during Q2 2022.
- Its 5-year average for Receivables is $3.2 million, with a median of $1.9 million in 2024.
- In the last 5 years, Denali Therapeutics' Receivables skyrocketed by 549500.0% in 2021 and then tumbled by 9787.31% in 2022.
- Denali Therapeutics' Receivables (Quarter) stood at $1.2 million in 2021, then surged by 657.1% to $9.3 million in 2022, then crashed by 63.15% to $3.4 million in 2023, then tumbled by 56.14% to $1.5 million in 2024, then increased by 26.67% to $1.9 million in 2025.
- Its Receivables stands at $1.9 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.7 million for Q1 2025.